123 related articles for article (PubMed ID: 6962779)
1. Phase I trial of 4-demethoxydaunorubicin with single i.v. doses.
Kaplan S; Martini A; Varini M; Togni P; Cavalli F
Eur J Cancer Clin Oncol; 1982 Dec; 18(12):1303-6. PubMed ID: 6962779
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses.
Kaplan S; Sessa C; Willems Y; Pacciarini MA; Tamassia V; Cavalli F
Invest New Drugs; 1984; 2(3):281-6. PubMed ID: 6595240
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of oral idarubicin given with a weekly schedule.
Dodion P; Finet C; Crespeigne N; Beer M; Nicaise C; Rozencweig M; Kenis Y
Invest New Drugs; 1986; 4(1):31-8. PubMed ID: 3457779
[TBL] [Abstract][Full Text] [Related]
4. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E
Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321
[TBL] [Abstract][Full Text] [Related]
5. Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer.
Berman E; Wittes RE; Leyland-Jones B; Casper ES; Gralla RJ; Howard J; Williams L; Baratz R; Young CW
Cancer Res; 1983 Dec; 43(12 Pt 1):6096-101. PubMed ID: 6580068
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical evaluation of oral and intravenous 4-demethoxydaunorubicin.
Kavanagh JJ; Yeung KY; Savaraj N; Krakoff IH
Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1187-9. PubMed ID: 3865774
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of 4-demethoxydaunorubicin.
Bonfante V; Ferrari L; Villani F; Bonadonna G
Invest New Drugs; 1983; 1(2):161-8. PubMed ID: 6590530
[TBL] [Abstract][Full Text] [Related]
8. Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.
Ganzina F; Pacciarini MA; Di Pietro N
Invest New Drugs; 1986; 4(1):85-105. PubMed ID: 3516918
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of Idarubicin (4-demethoxydaunorubicin) in adult acute leukemia.
Hayat M; Hurteloup P; Parmentier C; Carde P; Pico JO; Schlumberger M; Chahine G; Kamioner D
Invest New Drugs; 1984; 2(4):375-9. PubMed ID: 6595242
[TBL] [Abstract][Full Text] [Related]
10. Phase-I trial of 4-demethoxydaunorubicin in acute leukaemias.
Sessa C; Tschopp L; Fopp M; Cavalli F
Invest New Drugs; 1985; 3(4):357-9. PubMed ID: 3866755
[TBL] [Abstract][Full Text] [Related]
11. [A phase I trial of idarubicin by oral administration].
Ogawa M; Kimura K; Taguchi T; Wakui A; Hattori M; Shimoyama T; Fujita H
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1896-900. PubMed ID: 3473981
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of oral 4-demethoxydaunorubicin in previously treated (except anthracyclines) metastatic breast cancer patients.
Kolarić K; Mechl Z; Potrebica V; Sopkova B
Oncology; 1987; 44(2):82-6. PubMed ID: 3472133
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
Stuart NS; Cullen MH; Priestman TJ; Blackledge GR; Tyrrell CJ
Cancer Chemother Pharmacol; 1988; 21(4):351-4. PubMed ID: 3163529
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of idarubicin in patients with advanced lymphoma.
Gillies H; Liang R; Rogers H; Harper P; Parapia L; Cox G; Johnson S
Cancer Chemother Pharmacol; 1988; 21(3):261-4. PubMed ID: 3162850
[TBL] [Abstract][Full Text] [Related]
15. 4-Demethoxydaunorubicin administered orally in advanced breast cancer. A phase II study.
De Lena M; Brandi M; Bozzi D; Calabrese P; Romito S
Tumori; 1988 Feb; 74(1):65-70. PubMed ID: 3162625
[TBL] [Abstract][Full Text] [Related]
16. Activity of 4-demethoxydaunorubicin by the oral route in advanced breast cancer.
Martoni A; Pacciarini MA; Pannuti F
Eur J Cancer Clin Oncol; 1985 Jul; 21(7):803-6. PubMed ID: 3862582
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of 4-demethoxydaunorubicin in refractory epithelial ovarian cancer.
Kavanagh JJ; Copeland LJ; Gershenson DM; Saul PB; Edwards CL
Gynecol Oncol; 1986 May; 24(1):23-6. PubMed ID: 3457752
[TBL] [Abstract][Full Text] [Related]
18. Clinical phase I trial of marcellomycin with a single-dose schedule.
Nicaise C; Rozencweig M; de Marneffe M; Crespeigne N; Dodion P; Piccart M; Sculier JP; Lenaz L; Kenis Y
Eur J Cancer Clin Oncol; 1983 Apr; 19(4):449-54. PubMed ID: 6683182
[TBL] [Abstract][Full Text] [Related]
19. Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma.
Scher HI; Yagoda A; Ahmed T; Budman D; Sordillo P; Watson RC
Cancer Chemother Pharmacol; 1985; 14(1):79-80. PubMed ID: 3855289
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical study of 9-hydroxy-2N-methyl-ellipticinium acetate (NSC-264137) administered on a 5-day i.v. schedule.
Dodion P; Rozencweig M; Nicaise C; Piccart M; Cumps E; Crespeigne N; Kisner D; Kenis Y
Eur J Cancer Clin Oncol; 1982 Jun; 18(6):519-22. PubMed ID: 6889528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
